Rucaparib (also known as Rucaparib free base, AG-014447) is a Poly(ADP-ribose) polymerases (PARPs) inhibitor used as an anti-cancer agent.
Emergence of rationally designed therapeutic strategies for breast cancer targeting DNA repair mechanisms.
Central nervous system penetration and enhancement of temozolomide activity in childhood medulloblastoma models by poly(ADP-ribose) polymerase inhibitor AG-014699.
Novel targeted therapeutics: inhibitors of MDM2, ALK and PARP.
The potential for poly (ADP-ribose) polymerase inhibitors in cancer therapy.
Poly(ADP-ribose) polymerase inhibition: a new direction for BRCA and triple-negative breast cancer?
Compromised CDK1 activity sensitizes BRCA-proficient cancers to PARP inhibition.
Therapeutic potential of poly(ADP-ribose) polymerase inhibitor AG014699 in human cancers with mutated or methylated BRCA1 or BRCA2.
Phase 2 multicentre trial investigating intermittent and continuous dosing schedules of the poly(ADP-ribose) polymerase inhibitor rucaparib in germline BRCA mutation carriers with advanced ovarian and breast cancer.
Combination treatment with rucaparib (Rubraca) and MDM2 inhibitors, Nutlin-3 and RG7388, has synergistic and dose reduction potential in ovarian cancer.
Poly(ADP-Ribose) Polymerase Inhibitor PJ34 Attenuated Hepatic Triglyceride Accumulation in Alcoholic Fatty Liver Disease in Mice.
 B.P.Rowe, et al, Breast Cancer Res., 2010, 12(2), pp 1-11.
 R.A.Daniel, et al, Br. J. Cancer, 2010, 103(10), pp 1588-1596.
 Y.Yuan, et al, J. Hematol. Oncol., 2011, 4(16), pp 1-14.
 M. Javle, et al, Ther. Adv. Med. Oncol., 2011, 3(6), pp 257-267.
 R.Plummer, et al, Breast cancer Res., 2011, 13(4), pp 1-6.
 N.Johnson, et al, Nature Medicine, 2011, 17(7),pp 875-882.
 Y.Drew, et al, J. Natl. Cancer Inst., 2011, 103(4), pp 334-346.
 Y.Drew, et al, Br. J. Cancer., 2016, 114(7), pp 723-730.
 M.Zanjirband, et al, Oncotarget, 2017, 8(41), pp 69779-69796.
 S.Huang, et al, J. Pharmacol. Exp. Ther., 2018, 364(3), pp 452-461.